期刊文献+

Hepatitis C virus genotypes distribution and transmission risk factors in Luxembourg from 1991 to 2006 被引量:3

Hepatitis C virus genotypes distribution and transmission risk factors in Luxembourg from 1991 to 2006
下载PDF
导出
摘要 AIM:To analyze the Hepatitis C virus (HCV) genotype distribution and transmission risk factors in a population of unselected patients in Luxembourg. METHODS:Epidemiological information (gender, age and transmission risks) were collected from 802 patients newly diagnosed for hepatitis C and living in Luxembourg, among whom 228 patients referred from prison. Genotyping using 5'noncoding (5'NC) sequencing was performed. We compared categorical data using the Fisher's exact F-test and odds ratios (OR) were calculated for evaluating association of HCV genotype and risk factors. RESULTS:The sex ratio was predominantly male (2.2) and individuals aged less than 40 years represented 49.6% of the population. Genotype 1 was predominant (53.4%) followed by genotype 3 (33%). Among risk factors, intravenous drug usage (IVDU) was the most frequently reported (71.4%) followed by medical-related transmission (17.6%) including haemophilia, transfusion recipients and other nosocomial reasons. Genotype 3 was significantly associated to IVDU (OR = 4.84, P < 0.0001) whereas genotype 1 was significantly associated with a medical procedure (OR = 2.42, P < 0.001). The HCV genotype distribution from inmate patients differed significantly from the rest of the population (Chi-square test with four degrees of freedom, P < 0.0001) with a higher frequency of genotype 3 (46.5% vs 27.5%) and a lower frequency of genotype 1 and 4 (44.7% vs 56.8% and 5.3% vs 9.6%, respectively). IVDU was nearly exclusively reported as a risk factor in prison. CONCLUSION:We report the first description of the HCV genotype distribution in Luxembourg. The repartition is similar to other European countries, with one of the highest European prevalence rates of genotype 3 (33%). Since serology screening became available in 1991, IVDU remains the most common way of HCV transmission in Luxembourg. AIM: To analyze the Hepatitis C virus (HCV) genotype distribution and transmission risk factors in a population of unselected patients in Luxembourg. METHODS: Epidemiological information (gender, age and transmission risks) were collected from 802 patients newly diagnosed for hepatitis C and living in Luxembourg, among whom 228 patients referred from prison. Genotyping using 5'noncoding (5'NC) sequencing was performed. We compared categorical data using the Fisher's exact F-test and odds ratios (OR) were calculated for evaluating association of HCV genotype and risk factors. RESULTS: The sex ratio was predominantly male (2.2) and individuals aged less than 40 years represented 49.6% of the population. Genotype 1 was predominant (53.4%) followed by genotype 3 (33%). Among risk factors, intravenous drug usage (IVDU) was the most frequently reported (71.4%) followed by medical-related transmission (17.6%) including haemophilia, transfusion recipients and other nosocomial reasons. Genotype 3 was significantly associated to IVDU (OR = 4.84, P 〈 0.0001) whereas genotype 1 was significantly associated with a medical procedure (OR = 2.42, P 〈 0.001). The HCV genotype distribution from inmate patients differed significantly from the rest of the population (Chi-square test with four degrees of freedom, P 〈 0.0001) with a higher frequency of genotype 3 (46.5% vs 27.5%) and a lower frequency of genotype 1 and 4 (44.7% vs 56.8% and 5.3% vs 9.6%, respectively). IVDU was nearly exclusively reported as a risk factor in prison. CONCLUSION: We report the first description of the HCV genotype distribution in Luxembourg. The repartition is similar to other European counties, with one of the highest European prevalence rates of genotype 3 (33%). Since serology screening became available in 2992, IVDU remains the most common way of HCV transmission in Luxembourg.
出处 《World Journal of Gastroenterology》 SCIE CAS CSCD 2008年第8期1237-1243,共7页 世界胃肠病学杂志(英文版)
基金 The "Centre de Recherche Public-Santé" (CRP-Santé, project LRV-REC-06-01)
关键词 丙型肝炎病毒 基因型 卢森堡公国 致病因素 药品滥用 Hepatitis C virus Genotypes Luxembourg Risk factors Substance abuse Prisons
  • 相关文献

参考文献1

二级参考文献48

  • 1[1]Conry-Cantilena C,VanRaden M,Gibble J,Melpolder J,Shakil AO,Viladomiu L,Cheung L,DiBisceglie A,Hoofnagle J,Shih JW,Kaslow R,Ness P,Alter HJ.Routes of infection,viremia,and liver disease in blood donors found to have hepatitis C virus infection.N Engl J Med 1996; 334:1691-1696
  • 2[2]Alter MJ,Margolis HS,Krawczynski K,Judson FN,Mares A,Alexander WJ,Hu PY,Miller JK,Gerber MA,Sampliner RE.The natural history of community-acquired hepatitis C in the United States.The Sentinel Counties Chronic non-A,non-B Hepatitis Study Team.N Engl J Med 1992; 327:1899-1905
  • 3[3]Alter HJ,Conry-Cantilena C,Melpolder J,Tan D,Van Raden M,Herion D,Lau D,Hoofnagle JH.Hepatitis C in asymptomatic blood donors.Hepatology 1997; 26(Suppl 1):29-33
  • 4[4]Crofts N,Hopper JL,Milner R,Breschkin AM,Bowden DS,Locarnini SA.Blood-borne virus infections among Australian injecting drug users:implications for spread of HIV.Eur J Epidemiol 1994; 10:687-694
  • 5[5]Goldberg D,Cameron S,McMenamin J.Hepatitis C virus antibody prevalence among injecting drug users in Glasgow has fallen but remains high.Commun Dis Public Health 1998;1:95-97
  • 6[6]Samuel MC,Doherty PM,Bulterys M,Jenison SA.Association between heroin use,needle sharing and tattoos received in prison with hepatitis B and C positivity among streetrecruited injecting drug users in New Mexico,USA.Epidemiol Infect 2001; 127:475-484
  • 7[7]Alter MJ.Hepatitis C virus infection in the United States.J Hepatol 1999; 31:88-91
  • 8[8]Alavian SM,Gholami B,Masarrat S.Hepatitis C risk factors in Iranian volunteer blood donors:a case-control study.J Gastroenterol Hepatol 2002; 17:1092-1097
  • 9[9]Zali MR,Noroozi A,Amirrasooli H,Darvishi M.Prevalence of Anti-HCV antibody and routes of hematological transmission in addicts of Ghasr prison[in persian].Pajouhesh 1998;22:26-32
  • 10[10]Skipper C,Guy JM,Parkes J,Roderick P,Rosenberg WM.Evaluation of a prison outreach clinic for the diagnosis and prevention of hepatitis C:implications for the national strategy.Gut 2003; 52:1500-1504

共引文献4

同被引文献83

  • 1丙型肝炎防治指南[J].临床肝胆病杂志,2004,20(4):197-203. 被引量:735
  • 2杨东亮,郝连杰.我国丙型肝炎病毒基因变异及分型研究现状[J].中华传染病杂志,1996,14(1):41-44. 被引量:26
  • 3王敏,乐晓华,韩红星,蒋小玲,陆坚.HCV-RNA病毒载量和肝脏病理的关系[J].实用医学杂志,2006,22(13):1513-1514. 被引量:9
  • 4Joerg Timm,Michael Roggendorf.Sequence diversity of hepatitis C virus: Implications for immune control and therapy[J].World Journal of Gastroenterology,2007,13(36):4807-4817. 被引量:5
  • 5刘丽君,魏来.丙型肝炎病毒的流行病学[J].传染病信息,2007,20(5):261-264. 被引量:72
  • 6V. D. HOPE,I. ERAMOVA,D. CAPURRO,M. C. DONOGHOE.Prevalence and estimation of hepatitis B and C infections in the WHO European Region: a review of data focusing on the countries outside the European Union and the European Free Trade Association[J].Epidemiology and Infection.2013(2)
  • 7Gary L. Davis,Miriam J. Alter,Hashem El–Serag,Thierry Poynard,Linda W. Jennings.Aging of Hepatitis C Virus (HCV)-Infected Persons in the United States: A Multiple Cohort Model of HCV Prevalence and Disease Progression[J].Gastroenterology.2010(2)
  • 8Sylvie Deuffic–Burban,Pierre Deltenre,Maria Buti,Tommaso Stroffolini,Julie Parkes,Nikolai Mühlberger,Uwe Siebert,Christophe Moreno,Angelos Hatzakis,William Rosenberg,Stefan Zeuzem,Philippe Mathurin.Predicted Effects of Treatment for HCV Infection Vary Among European Countries[J].Gastroenterology.2012(4)
  • 9Oliver G. Pybus,Eleanor Barnes,Rachel Taggart,Philippe Lemey,Peter V. Markov,Bouachan Rasachak,Bounkong Syhavong,Rattanaphone Phetsouvanah,Isabelle Sheridan,Isla S. Humphreys,Ling Lu,Paul N. Newton,Paul Klenerman.Genetic History of Hepatitis C Virus in East Asia. Journal of Virology . 2009
  • 10Lauer GM,Walker BD.Hepatitis C virus infection. New England Journal of Medicine, The . 2001

引证文献3

二级引证文献78

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部